Teva Pharmaceutical Industries, Ltd. (NASDAQ: TEVA) announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) reducing medication and food restrictions. This update was based on clinical data that confirmed the mechanism of action of AZILECT® as a selective MAO-B (monoamine oxidase-B) inhibitor at the recommended doses of 1 mg and 0.5 mg…

Here is the original: 
FDA Approves Newly Revised Prescribing Information For AZILECT(R) Reducing Medication And Food Restrictions

Related posts:

1. Thyroid Journal Publishes Newly Revised Guidelines For Managing Thyroid CancerThe American Thyroid Association has released new, revised Management Guidelines for the diagnosis and treatment of patients with thyroid nodules and thyroid cancer. The new guidelines are published in Thyroid,...
2. FDA Approves ZEGERID OTC(TM) For Over-the-Counter Treatment Of Frequent HeartburnMerck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ZEGERID OTC(TM) (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules), for over-the-counter treatment of frequent heartburn....
3. FDA Approves Intravenous Formulation Of Pfizer’s Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial HypertensionPfizer announced that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in...
4. FDA Approves Lilly’s Zyprexa For Two Adolescent IndicationsThe U.S. Food and Drug Administration (FDA) approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I...
5. FDA Approves New Drug For Rare Cancer Cutaneous T-Cell LymphomaThe US Food and Drug Administration (FDA) has approved a new drug for treating patients with the rare white blood cell cancer Cutaneous T-cell Lymphoma (CTCL); the drug Istodax (romidepsin)...
6. FDA Approves Generic Aricept To Treat Dementia Related To Alzheimer’s DiseasePlease note this is a corrected version of a press release that was posted to FDA's website today. The corrections include a modified headline and a revised second paragraph. The...
7. US FDA Approves SEROQUEL XR(R) For Add-On Treatment Of Major Depressive DisorderAstraZeneca (NYSE: AZN) announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults...
8. FDA Approves New Drug For Pain That Persists After ShinglesThe US Food and Drug Administration (FDA) announced yesterday that it has approved Qutenza (capsaicin) 8% patch for the treatment of post-herpetic neuralgia (PHN), an often excruciating pain that can...
9. FDA Approves Agriflu Seasonal Influenza VaccineThe U.S. Food and Drug Administration approved Agriflu for people ages 18 years and older to prevent disease caused by influenza virus subtypes A and B. ...
10. FDA Approves Kalbitor For Treating Potentially Life-Threatening Attacks Of Hereditary AngioedemaThe U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition...
11. FDA Approves Gloucester Pharmaceuticals’ ISTODAX(R) For Patients With Cutaneous T-cell LymphomaGloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least...
12. FDA Approves Gloucester Pharmaceuticals’ ISTODAX(R) For Patients With Cutaneous T-cell LymphomaGloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least...
13. FDA Approves New Salix Product Exclusively In Catalent’s Zydis(R) Fast Dissolve TechnologyCatalent Pharma Solutions, one of the leading advanced drug delivery technology providers to the pharmaceutical industry, announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for...
14. FDA Approves Lysteda To Treat Heavy Menstrual BleedingThe U.S. Food and Drug Administration approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps...
15. FDA Approves New Drug Treatment For Long-Term Pain Relief After Shingles AttacksThe Food and Drug Administration (FDA) has approved the approval of Qutenza (capsaicin) 8% patch, a medicated skin patch that relieves the pain of post-herpetic neuralgia (PHN), a serious complication...